Gain Therapeutics Future Growth
Future criteria checks 0/6
Gain Therapeutics's revenue and earnings are forecast to decline at 2.2% and 18.9% per annum respectively while EPS is expected to decline by 11.6% per annum.
Key information
-18.9%
Earnings growth rate
-11.6%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | -2.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 25 Nov 2024 |
Recent future growth updates
Recent updates
Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
May 29Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential
Jan 12Gain Therapeutics appoints CEO
Sep 20Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value
Oct 27Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing
Aug 19Gain Therapeutics EPS misses by $0.29
May 10Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -33 | N/A | N/A | 2 |
| 12/31/2025 | 0 | -25 | N/A | N/A | 4 |
| 12/31/2024 | N/A | -21 | N/A | N/A | 5 |
| 9/30/2024 | N/A | -21 | -21 | -21 | N/A |
| 6/30/2024 | N/A | -22 | -19 | -19 | N/A |
| 3/31/2024 | N/A | -21 | -18 | -18 | N/A |
| 12/31/2023 | 0 | -22 | -19 | -19 | N/A |
| 9/30/2023 | 0 | -22 | -17 | -17 | N/A |
| 6/30/2023 | 0 | -22 | -17 | -16 | N/A |
| 3/31/2023 | 0 | -19 | -17 | -16 | N/A |
| 12/31/2022 | 0 | -18 | -15 | -15 | N/A |
| 9/30/2022 | 0 | -16 | -15 | -15 | N/A |
| 6/30/2022 | 0 | -16 | -14 | -14 | N/A |
| 3/31/2022 | 0 | -15 | -12 | -12 | N/A |
| 12/31/2021 | 0 | -14 | -12 | -12 | N/A |
| 9/30/2021 | 0 | -12 | -10 | -10 | N/A |
| 6/30/2021 | 0 | -8 | -8 | -8 | N/A |
| 3/31/2021 | N/A | -5 | -5 | -5 | N/A |
| 12/31/2020 | N/A | -4 | -3 | -3 | N/A |
| 9/30/2020 | N/A | -3 | -2 | -2 | N/A |
| 12/31/2019 | N/A | -2 | -2 | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GANX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GANX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GANX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GANX's revenue is expected to decline over the next 3 years (-2.2% per year).
High Growth Revenue: GANX's revenue is forecast to decline over the next 3 years (-2.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GANX's Return on Equity is forecast to be high in 3 years time